Abstract:Accumulating data suggests that the extent of lymphocytic infiltrations into the tumor provides prognostic value in non-small cell lung cancer (NSCLC). However, the factors that influence the status of tumor immune environment remain poorly defined and need investigation. The aim of this study was to assess whether the density of tumor infiltrating lymphocytes (TILs) was related to tumor molecular characteristics in completely resected stage IIIA(N2) lung adenocarcinoma. We retrospectively screened consecutive patients with pathologic stage IIIA(N2) pulmonary adenocarcinomas, who had undergone complete resection in our hospital between 2005 and 2012. Patients who received neoadjuvant chemotherapy and/or radiotherapy were excluded. DNA of EGFR and KRAS was extracted and purified from paraffin-embedded primary lung cancer tissue samples. EGFR (exons 18-21) and KRAS (exons 2, 3) mutation analyses were performed by the DNA sequencing. The density of TILs was evaluated by full-face hematoxylin- and eosin-stained sections from surgical specimens for each case by two specialized pathologists. The degree of lymphocyte infiltration into the tumor was scored as none, low, moderate, or high. Patients were stratified into TIL- (none to low infiltration) or TIL+ (moderate to high infiltration) group based on pathologic evaluation. We investigated the association of densities of TILs with tumor-cell mutation status. Among the 192 eligible patients included, 96 (50%) patients were male and 123 (64%) were never/light ex-smokers, and the median age of all patients was 59 years (range, 22–84 years). There were 84 (43.8%) EGFR mutated and 21 (10.9%) KRAS mutated cases. Among the 84 patients with activating EGFR mutations, there were 30 patients harboring mutations in the exon 19 deletions, 35 patients in the exon 21 L858R mutations, and 1 patient with concurrent exon 19 deletion and L858R mutation. The proportion of patients who had higher density of TILs (TIL+) was lower in the EGFR mutation-positive subgroup (42.9% versus 53.7%, P=0.14) and this difference was significantly observed in the patients with L858R mutation and/or exon 19 deletion subgroup (P=0.026). The proportion of patients who had higher density of TILs (TIL+) was significantly lower in the 66 patients harboring L858R mutation and/or exon 19 deletion (37.9% versus 54.8%, P=0.026). There existed association between the lower density of TILs and activating EGFR mutation status in lung adenocarcinoma, underlying the interactions between cancer cells and their microenvironment. Further studies are warranted to validate these results and clarify the potential molecular mechanisms responsible for regulation of lymphocytic infiltration by activating EGFR pathway.

EP03.03-06 The Involvement of Tumor Endothelial Cells in the Regulation of PD-L1 and Tregs in the Immune Microenvironment of Early-stage Lung Adenocarcinoma

Single-cell and spatial transcriptome characterize coinhibitory cell-cell communications during histological progression of lung adenocarcinoma

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

Characterizing Tumor Microenvironment and Risk Genes in Lung Adenocarcinoma through scRNA-seq and Bulk RNA-seq Data

The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD‐L1 expression and tumor‐infiltrating lymphocytes

Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single‐cell transcriptomic analysis: Implications for distinct immunotherapy outcomes

Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution

Landscape and dynamics of single tumor and immune cells in early and advanced-stage lung adenocarcinoma.

Role and mechanism of LINC02390 and its potential target genes, CLECL1 and CD69, in immune microenvironment of lung adenocarcinoma

Immune and non-immune cell subtypes identify novel targets for prognostic and therapeutic strategy: A study based on intratumoral heterogenicity analysis of multicenter scRNA-seq datasets in lung adenocarcinoma

P2.01-057 Association of Tumor Infiltrating Lymphocytes Quantification with EGFR Mutations in Completely Resected Stage IIIA(N2) Lung Adenocarcinoma: Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy

In-depth genomic characterization of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients.

Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment

Spatial transcriptomics reveals heterogeneity of histological subtypes between lepidic and acinar lung adenocarcinoma

The Predictive Role of Immune Related Subgroup Classification in Immune Checkpoint Blockade Therapy for Lung Adenocarcinoma

Integrative analysis of single-cell and bulk RNA-sequencing data revealed T cell marker genes based molecular sub-types and a prognostic signature in lung adenocarcinoma

Single-cell and Bulk RNA-Seq reveal angiogenic heterogeneity and microenvironmental features to evaluate prognosis and therapeutic response in lung adenocarcinoma

EP03.03-08 Single-nucleus RNA Sequencing Dissecting the Tumor Microenvironment of Liver Metastasis of Non-small Cell Lung Cancer

Spatiotemporal Profiling Unveiling the Cellular Organization Patterns and Local Protumoral Immune Microenvironment Remodeling in Early Lung Adenocarcinoma Progression

Single-cell analyzing of tumor microenvironment and cell adhesion between early and late-stage lung cancer